A small French pharmaceutical company has discovered a way to help the world's millions of peanut allergy sufferers. The company, DBV Technologies, has developed a patch similar to a nicotine patch that people wear on their skin to increase their tolerance to peanuts. In the most recent testing round of the drug, called Viaskin Peanut, some peanut allergy sufferers were able to eat as many as four peanuts without experiencing any problems.
The drug has received fast-track testing approval by the U.S. Food and Drug Administration and is already far along in the testing stages. DBV Technologies expects to start selling the drug in the U.S. by the first half of the year in 2018.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Swiss bliss: Chenot Palace Weggis takes wellness to the next levelThe Blend Heath retreat on Switzerland's Lake Lucerne offers a mid-winter reset
-
Earth's mini-moon was the moon all alongUnder the radar More lunar rocks are likely floating in space
-
Crossword: February 4, 2025The Week's daily crossword
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstancesSpeed Read
-
Western mountain climbers allegedly left Pakistani porter to die on K2Speed Read
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governorSpeed Read
-
Los Angeles city workers stage 1-day walkout over labor conditionsSpeed Read
-
Mega Millions jackpot climbs to an estimated $1.55 billionSpeed Read
-
Bangladesh dealing with worst dengue fever outbreak on recordSpeed Read
-
Glacial outburst flooding in Juneau destroys homesSpeed Read
-
Scotland seeking 'monster hunters' to search for fabled Loch Ness creatureSpeed Read
